nach oben

Erschienen in:

01.01.2016 | Original Article

The amount of citrullinated proteins in synovial tissue is related to serum anti-cyclic citrullinated peptide (anti-CCP) antibody levels

verfasst von: Elizabeth Olivares-Martínez, Diego F. Hernández-Ramírez, Carlos A. Núñez-Álvarez, Antonio R. Cabral, Luis Llorente

Erschienen in: Clinical Rheumatology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to determine the relationship between citrullinated proteins in synovial tissue with peripheral anti-citrullinated peptides autoantibodies (ACPA) and peptidylarginine deiminase (PADI) PADI2, PADI3, and PADI4 messenger RNA (mRNA) expressions in synovial tissue and fibroblast-like synoviocytes in rheumatoid arthritis (RA) patients. Eleven RA and 12 osteoarthritis (OA) patients who underwent knee replacement surgery were studied. We detected citrullinated proteins in synovial tissue homogenates by western blot and serum ACPA by ELISA to anti-cyclic citrullinated peptide (anti-CCP) antibodies, and PADI2, PADI3, and PADI4 mRNA expressions in synovial tissue and in fibroblast-like synoviocytes. Patients with high amount of citrullinated proteins in synovial tissue (3 out of 7) have high levels of anti-CCP in serum. However, in the remaining 4 patients, the amount of synovial citrullinated proteins was minimal and their sera showed low levels of anti-CCP antibodies. Furthermore, we observed an increase in PADI2 mRNA expression in RA synovial tissue compared with OA patients (p = 0.02). We detected PADI3 mRNA in the synovial tissue of RA patients, but not in the tissue of OA patients. Even though fibroblast-type synoviocytes in RA are not the main source of PADs in the synovial tissue, they express PADI2 mRNA moderately, PADI4 mRNA weakly, while there is no detectable expression of PADI3 mRNA. In conclusion, we found a variety of citrullinated proteins in the synovial tissue of RA patients and the amount of such proteins is related to serum concentration of anti-CCP antibodies. We identified the presence of PADI3 mRNA expression in synovial tissue and PADI2 and PADI4 mRNA expressions in fibroblast-like synoviocytes from patients with RA.

Van Venrooij WJ, Pruijn GJ (2000) Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res 2:249–251PubMedPubMedCentralCrossRef

Nielen MN, van Schaardenburg D, Reesink HW et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380–386PubMedCrossRef

Tarcsa E, Marecov L, Mei G et al (1996) Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationship of the natural substrates trichohyalin and filaggrin. J Biol Chem 271:30709–30716PubMedCrossRef

Foulquier C, Sebbag M, Clavel C et al (2007) Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 56:3541–3553PubMedCrossRef

Giles JT, Darrah E, Danoff S et al (2014) Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease. PLoS One 9, e98794. doi:10.1371/journal.pone.0098794 PubMedPubMedCentralCrossRef

Vossenaar ER, Radstake TR, van der Heijden A et al (2004) Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 63:373–381PubMedPubMedCentralCrossRef

Asaga HK, Kakashima T, Senshu A et al (2001) Immunocytochemical localization of peptidylarginine deiminase in human eosinophils and neutrophils. J Leukocyte Biol 70:46–51PubMed

Chang X, Yamada R, Suzuki A (2005) Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein synovial tissue of rheumatoid arthritis. Rheumatology 44:40–50PubMedCrossRef

Neumann E, Lefevre S, Zimmermann B, Gay S et al (2010) Rheumatoid arthritis progression mediated by activated synovial fibroblast. Trends Mol Med 10:458–58CrossRef

10.

Vossenaar ER, Smeets TJ, Kraan MC et al (2004) The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 50:3485–3494PubMedCrossRef

11.

Schellekens GA, Visser H, de Jong BAW et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognized a cyclic citrullinated peptide. Arthritis Rheum 43:155–163PubMedCrossRef

12.

Matsuo K, Xiang Y, Nakamura H et al (2006) Identification of novel citrullinated autoantigens of synovium in rheumatoid arthritis using a proteomic approach. Arthritis Res Ther 8:R175PubMedPubMedCentralCrossRef

13.

Lundberg K, Nijenhuis S, Vossenaar ER et al (2005) Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 7:R458PubMedPubMedCentralCrossRef

14.

Hill JA, Bell DA, Brintnell W et al (2003) The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 171:538–541PubMedCrossRef

15.

Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef

16.

Müller-Ladner U, Ospelt C, Gay S et al (2007) Synovial fibroblasts. Arthritis Res Ther 9:R223CrossRef

17.

Zhao X, Okeke NL, Sharpe O et al (2008) Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther 10:R94PubMedPubMedCentralCrossRef

18.

Hermansson M, Artemenko K, Ossipova E et al (2010) MS analysis of rheumatoid arthritic synovial tissue identifies specific citrullination sites on fibrinogen. Proteomics Clin Appl 4:511–518PubMed

19.

Suzuki A, Yamada R, Ohtake-Yamanaka M et al (2005) Anti-citrullinated collagen type I antibody is a target of autoimmunity in rheumatoid arthritis. Biochem Biophys Res Commun 333:418–426PubMedCrossRef

20.

Yoshida M, Tsuji M, Kurosaka D et al (2006) Autoimmunity to citrullinated type II collagen in rheumatoid arthritis. Mod Rheumatol 18:429–441

21.

Tilleman K, van Steendam K, Cantaert T et al (2008) Synovial detection and autoantibody reactivity of processed citrullinated isoforms of vimentin in inflammatory arthritides. Rheumatology 47:597–604PubMedCrossRef

22.

Kinloch A, Tatzer V, Wait R et al (2005) Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 7:R1421PubMedPubMedCentralCrossRef

23.

Klareskog L, Stolt P, Lundberg K et al (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54:38–46PubMedCrossRef

24.

Marchant C, Smith M, Proudman S et al (2013) Effect of porphyromonas gingivalis on citrullination of proteins by macrophages in vitro. J Periodontol 84:1272–1280PubMedCrossRef

25.

Rutger PG (2012) Rheumatoid arthritis and periodontitis-inflammatory and infectious connections. J Oral Microbiol 4:11829

26.

Bongartz T, Cantaert T, Atkins SR et al (2007) Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology 46:70–75PubMedCrossRef

27.

Makrygiannakis D, Shankar R, Engströnm M et al (2012) Local administration of glucocorticoids decreased synovial citrullination in rheumatoid arthritis. Arthritis Res Ther 14:R20PubMedPubMedCentralCrossRef

28.

Daha NA, Toes RE (2011) Rheumatoid arthritis: are ACPA-positive and ACPA-negative RA the same disease? Nat Rev Rheumatol 7:202–203PubMedCrossRef

29.

Ohmura K, Terao C, Maruya E et al (2010) Anti-citrullinated peptide antibody negative RA is a genetically distinct subset: a definitive study using only bone erosive ACPA negative rheumatoid arthritis. Rheumatology 49:2298–2304PubMedPubMedCentralCrossRef

30.

Suzuki A, Yamada R, Chang X et al (2003) Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genetics 34:395–402PubMedCrossRef

31.

Chang X, Han J (2006) Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors. Mol Carcinog 45:183–196PubMedCrossRef

32.

Wang Y, Wysocka J, Sayegh J et al (2004) Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306:279–283PubMedCrossRef

33.

Dong S, Zhang Z, Takahara H (2007) Estrogen-enhanced peptidylarginine deiminase type IV gene (PADI4) expression in MCF-7 cells is mediated by estrogen receptor-α-promoted transfactors activator protein-1, nuclear factor-Y and Sp1. Mol Edocrinol 21:1617–1629CrossRef

34.

Nakashima K, Arai S, Nariai Y et al (2013) PAD4 regulates proliferation of multipotent haematopoietic cells by controlling c-myc expression. Nat Commun 4:1836PubMedPubMedCentralCrossRef

35.

Chang X, Yamada R, Suzuki A et al (2005) Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology 44:1374–1382PubMedCrossRef

Titel: The amount of citrullinated proteins in synovial tissue is related to serum anti-cyclic citrullinated peptide (anti-CCP) antibody levels
verfasst von: Elizabeth Olivares-Martínez
Diego F. Hernández-Ramírez
Carlos A. Núñez-Álvarez
Antonio R. Cabral
Luis Llorente
Publikationsdatum: 01.01.2016
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 1/2016
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-015-3047-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Enhancing the care of women with rheumatic diseases during pregnancy: challenges and unmet needs in the Middle East

A rare cause for lower back pain: a case of an IgG4-related periaortitis

Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures

Juvenile idiopathic arthritis activity and function ability: deleterious effects in periodontal disease?

Time trends in total ankle arthroplasty in the USA: a study of the National Inpatient Sample

Serum IL8 and mRNA level of CD11b in circulating neutrophils are increased in clinically amyopathic dermatomyositis with active interstitial lung disease